Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder.
Two multicenter, double-blind, placebo-controlled clinical trials were conducted to evaluate the effectiveness of 10 weeks of treatment with up to 300 mg daily of clomipramine in nondepressed patients with OCD. There were 575 patients enrolled in these clinical trials, and preliminary analyses of data from 384 of these patients demonstrate a virtual absence of placebo response, a very low rate of premature discontinuation, and for patients receiving clomipramine, a statistically and clinically significant improvement in OCD symptoms (40%-45% mean improvement with clomipramine vs. 4%-5% mean improvement with placebo). In general, clomipramine was well tolerated in doses of up to 300 mg daily.
DeVeaugh-Geiss
J
J
Landau
P
P
Katz
R
R
D002986:Clinical Trials as Topic; D002997:Clomipramine / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D015337:Multicenter Studies as Topic; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D011897:Random Allocation
D002997:Clomipramine